Ocular Therapeutix Reports Q4 Revenue Decline, Expects Phase 3 Wet AMD Trial Data in February 2026

Ocular Therapeutix reported Q4 revenue of $13.3mln, a decline from $17.1mln YoY. The company's lead program, AXPAXLI, is in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease. Topline results for SOL-1, the Phase 3 superiority trial in wet AMD, are expected at the 49th Macula Society Annual Meeting in February 2026. Ocular has a strong cash position with $737.1mln in cash and cash equivalents as of December 31, 2025, providing runway into 2028.